Investigating the effects of dopamine on short‐ and long‐latency afferent inhibition
The Journal of Physiology · 2024
DOI: 10.1113/jp286126 ↗At a glance
Randomisierte kontrollierte Studie in The Journal of Physiology, 2024. Written by Stevie D Foglia and 7 co-authors. Institution: School of Biomedical Engineering, McMaster University, Hamilton, Ontario, Canada. Major MEDLINE topics: Levodopa, Evoked Potentials, Motor, Transcranial Magnetic Stimulation, Carbidopa. 54 references. The full text is freely available (open access, CC BY 4.0). Funded by: Natural Sciences and Engineering Research Council of Canada.
Abstract (original language)
Short‐ and long‐latency afferent inhibition (SAI and LAI respectively) are phenomenon whereby the motor evoked potential induced by transcranial magnetic stimulation (TMS) is inhibited by a sensory afferent volley consequent to nerve stimulation. It remains unclear whether dopamine participates in the genesis or modulation of SAI and LAI. The present study aimed to determine if SAI and LAI are modulated by levodopa ( l ‐DOPA). In this placebo‐controlled, double‐anonymized study Apo‐Levocarb (100 mg l ‐DOPA in combination with 25 mg carbidopa) and a placebo were administered to 32 adult males (mean age 24 ± 3 years) in two separate sessions. SAI and LAI were evoked by stimulating the median nerve and delivering single‐pulse TMS over the motor hotspot corresponding to the first dorsal interosseous muscle of the right hand. SAI and LAI were quantified before and 1 h following ingestion of drug or placebo corresponding to the peak plasma concentration of Apo‐Levocarb. The results indicate that Apo‐Levocarb increases SAI and does not significantly alter LAI. These findings support literature demonstrating increased SAI following exogenous dopamine administration in neurodegenerative disorders. image Key points Short‐ and long‐latency afferent inhibition (SAI and LAI respectively) are measures of corticospinal excitability evoked using transcranial magnetic stimulation. SAI and LAI are reduced in conditions such as Parkinson's disease which suggests dopamine may be involved in the mechanism of afferent inhibition. 125 mg of Apo‐Levocarb (100 mg dopamine) increases SAI but not LAI. This study increases our understanding of the pharmacological mechanism of SAI and LAI.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- School of Biomedical Engineering, McMaster University, Hamilton, Ontario, Canada.
- Department of Kinesiology, McMaster University, Hamilton, Ontario, Canada.
- Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Alberta, Canada.
- Department of Pediatrics, McMaster University, Hamilton, Ontario, Canada.
- Department of Health Research Methods, Evidence, and Impact, McMaster University, Hamilton, Ontario, Canada.
ORCID profiles: Mark Tarnopolsky, Jinhui Ma, Aimee J Nelson
Funding
- Natural Sciences and Engineering Research Council of Canada
Cite
APA
Foglia, S. D., Adams, F. C., Ramdeo, K. R., Drapeau, C. C., Turco, C. V., Tarnopolsky, M., Ma, J., & Nelson, A. J. (2024). Investigating the effects of dopamine on short‐ and long‐latency afferent inhibition. The Journal of Physiology. https://doi.org/10.1113/jp286126
Vancouver
Foglia SD, Adams FC, Ramdeo KR, Drapeau CC, Turco CV, Tarnopolsky M, et al. Investigating the effects of dopamine on short‐ and long‐latency afferent inhibition. The Journal of Physiology. 2024. doi:10.1113/jp286126
BibTeX
@article{Foglia2024,
author = {Foglia, Stevie D and Adams, Faith C and Ramdeo, Karishma R and Drapeau, Chloe C and Turco, Claudia V and Tarnopolsky, Mark and Ma, Jinhui and Nelson, Aimee J},
title = {Investigating the effects of dopamine on short‐ and long‐latency afferent inhibition},
journal = {The Journal of Physiology},
year = {2024},
doi = {10.1113/jp286126}
}
EUVIMED